Clearside Biomedical (CLSD.Q) Stock Overview
A biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
CLSD.Q Community Fair Values
Create NarrativeSee what 6 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Looking to be second time lucky with a game-changing new product
Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.
Read full narrativeClearside Biomedical, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.31 |
| 52 Week High | US$14.09 |
| 52 Week Low | US$0.11 |
| Beta | 1.86 |
| 1 Month Change | 19.23% |
| 3 Month Change | -54.61% |
| 1 Year Change | -97.68% |
| 3 Year Change | -98.07% |
| 5 Year Change | -99.13% |
| Change since IPO | -99.71% |
Recent News & Updates
Recent updates
CLSD.Q: Bankruptcy Sale Process Will Unlock Significant Equity Upside
Analysts have sharply raised their price target on Clearside Biomedical to approximately 90 dollars from 6 dollars, citing a reassessment of fair value despite more conservative assumptions on revenue growth, profitability, and required returns. What's in the News Clearside Biomedical filed for Chapter 11 bankruptcy protection in the U.S. Bankruptcy Court for the District of Delaware, listing assets of 1 to 10 million dollars and liabilities of 50 to 100 million dollars (court filing).
FDA Alignment And Phase 3 Trials Will Advance AMD Therapy
Despite a significant increase in the consensus analyst price target from $4.00 to $60.00, analysts remain cautious due to Clearside's uncertain strategic direction, tough financing environment, and diminishing cash runway, which cloud visibility into the company's future. Analyst Commentary Announcement of exploring strategic alternatives created uncertainty around Clearside's future direction.
FDA Alignment And Phase 3 Trials Will Advance AMD Therapy
FDA alignment on CLS-AX for wet AMD and Phase 2b outcomes may boost revenues and market leadership upon approval.Here's Why We're Watching Clearside Biomedical's (NASDAQ:CLSD) Cash Burn Situation
We can readily understand why investors are attracted to unprofitable companies. For example, although...We're Keeping An Eye On Clearside Biomedical's (NASDAQ:CLSD) Cash Burn Rate
Just because a business does not make any money, does not mean that the stock will go down. For example, although...Here's Why We're Not At All Concerned With Clearside Biomedical's (NASDAQ:CLSD) Cash Burn Situation
Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...Analyst Forecasts Just Became More Bearish On Clearside Biomedical, Inc. (NASDAQ:CLSD)
The analysts covering Clearside Biomedical, Inc. ( NASDAQ:CLSD ) delivered a dose of negativity to shareholders today...Clearside Biomedical Q2 2022 Earnings Preview
Clearside Biomedical (NASDAQ:CLSD) is scheduled to announce Q2 earnings results on Tuesday, August 9th, before market open. The consensus EPS Estimate is -$0.13 (-18.2% Y/Y) and the consensus Revenue Estimate is $0.3M (-61.5% Y/Y). Over the last 3 months, EPS estimates have seen 1 upward revision and 2 downward. Revenue estimates have seen 0 upward revisions and 1 downward.Clearside Biomedical: A Pivotal 2022 Ahead
XIPERE was officially launched by partner Bausch + Lomb in Q1 2022. CLS-AX cohort 3 has fully enrolled with a fourth cohort to be enrolled Q2 2022 pending safety review of cohort 3. Partner Aura Biosciences will select the route of administration for lead drug candidate AU-011. Clearside is actively seeking gene therapy partners.Clearside's Safety Data In Wet AMD And Emphasis On SCS Microinjector Make It Great Speculative Play
Clearside Biomedical reported positive safety data from phase 1/2a study using SCS microinjector for suprachoroidal delivery in patients with wet age-related macular degeneration. Clearside Biomedical and its partner Bausch & Lomb received FDA approval of first suprachoroidal injection drug XIPERE for treatment of patients with macular edema associated with uveitis. XIPERE is expected to launch in the 1st half of 2022, and Clearside has already received a $19 million pre-commercial milestone payment for it. Other established pharmaceutical companies exploring the use of the SCS microinjector for suprachoroidal delivery of their eye drugs are REGENXBIO and Aura Biosciences.Clearside Biomedical (NASDAQ:CLSD) Is In A Strong Position To Grow Its Business
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Clearside's Value Proposition Is Far From Clear
Clearside is developing treatments for diseases of the suprachoroidal space of the eye. However, even its latest stage asset has very little monetary value. Self-owned programs are in early stages and face stiff competition.We Think Clearside Biomedical (NASDAQ:CLSD) Can Easily Afford To Drive Business Growth
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Shareholder Returns
| CLSD.Q | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | -1.6% | -1.9% | 2.2% |
| 1Y | -97.7% | 33.5% | 31.1% |
Return vs Industry: CLSD.Q underperformed the US Pharmaceuticals industry which returned 33.5% over the past year.
Return vs Market: CLSD.Q underperformed the US Market which returned 31.1% over the past year.
Price Volatility
| CLSD.Q volatility | |
|---|---|
| CLSD.Q Average Weekly Movement | 44.2% |
| Pharmaceuticals Industry Average Movement | 9.9% |
| Market Average Movement | 7.3% |
| 10% most volatile stocks in US Market | 16.1% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: CLSD.Q's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: CLSD.Q's weekly volatility has increased from 34% to 44% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2011 | 32 | George Lasezkay | clearsidebio.com |
Clearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. The company offers XIPERE, a triamcinolone acetonide injectable suspension for the treatment of macular edema associated with uveitis. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which has completed Phase 2 clinical trial to treat wet AMD.
Clearside Biomedical, Inc. Fundamentals Summary
| CLSD.Q fundamental statistics | |
|---|---|
| Market cap | US$1.62m |
| Earnings (TTM) | -US$26.00m |
| Revenue (TTM) | US$3.33m |
Is CLSD.Q overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CLSD.Q income statement (TTM) | |
|---|---|
| Revenue | US$3.33m |
| Cost of Revenue | US$397.00k |
| Gross Profit | US$2.93m |
| Other Expenses | US$28.93m |
| Earnings | -US$26.00m |
Last Reported Earnings
Sep 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -4.97 |
| Gross Margin | 88.07% |
| Net Profit Margin | -780.90% |
| Debt/Equity Ratio | -113.4% |
How did CLSD.Q perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/05/11 12:54 |
| End of Day Share Price | 2026/05/08 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Clearside Biomedical, Inc. is covered by 8 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Esther Lannie Hong | Brean Capital Historical (Janney Montgomery) |
| Debanjana Chatterjee | JonesTrading Institutional Services, LLC |
| Anupam Rama | J.P. Morgan |